mini-reviews in medicinal chemistry, 2007, 7, 1108-1119

1108

privileged structures: a useful concept for the rational design of new
lead drug candidates
carolina d. duarte, eliezer j. barreiro and carlos a.m. fraga*
laboratório de avaliação e síntese de substâncias bioativas (lassbio, http://www.farmacia.ufrj.br/lassbio), faculdade
de farmácia, universidade federal do rio de janeiro, p.o. box 68023, zip 21944-971, rio de janeiro, rj, brazil
abstract: privileged structures are defined as molecular frameworks which are able of providing useful ligands for more
than one type of receptor or enzyme target by judicious structural modifications. in the present work, we describe some
examples and applications of the usefulness of the privileged structure concept for the structural design of new drug candidates, by discussing the eligibility of such motifs, including the identification of the n-acylhydrazone template as privileged structures.

key words: privileged structures, pharmacophoric point, rational drug design, bioactive n-acylhydrazones derivatives.
introduction
medicinal chemistry focuses on the aspects related to the
structural design, invention, discovery, identification and synthesis of therapeutically interesting compounds, i.e. pharmaceuticals, as well as the molecular reasons of their mechanism of action, including the understanding of the factors
involved in the structure-activity relationships, absorption,
distribution, metabolism, elimination and toxicity [1-2].
the molecular recognition of a drug in the biophase is
resultant from intermolecular interactions with biomacromolecules, involving electrostatic forces, dispersion and hydrophobic interactions, hydrogen and covalent bonds [3-4].
the spatial arrangement of structural subunits of micromolecule, responsible for these interactions with the complementary sites of the target bioreceptor, includes the pharmacophoric requisites for its recognition, and defines qualitatively the affinity and selectivity degree of drug–bioreceptor complex [3-4].
in the recent literature, it is noticed great interest in the
identification of molecular frameworks called privileged
structures, which correspond to the minimum structural subunit, usual in several drugs or lead-compounds, able of providing ligand points for more than one type of bioreceptor
[5-6]. this concept was firstly formulated by evans [5] and
improved later by patchett and nargund [6], who identified
properties in these substructures that make their interaction
with biomacromolecules easier and occasionally distinct
from the ones that involve the respective endogenous ligands.
moreover, from the identification of a privileged structure,
the desired selectivity may be modulated through supplementary molecular modifications involving other subunits or
auxophoric groups. the adoption of this new concept has
caused expressive impact on the development of the modern
*address correspondence to this author at laboratório de avaliação e síntese de substâncias bioativas (lassbio,), faculdade de farmácia, universidade federal do rio de janeiro, p.o. box 68023, zip 21944-971, rio de
janeiro, rj, brazi; tel: +55-21-22609192; fax: +55-21-25626478;
e-mail: cmfraga@pharma.ufrj.br

1389-5575/07 $50.00+.00

medicinal chemistry, as it may be noticed by the significant
growing of the annual number of citations of the expression
“privileged structures” in different databases [7] (fig. (1)).
use of privileged structures concept in
the rational design of new chemical libraries:
since the 1990’s, with the use of the combinatory chemistry techniques and robotized screening (high throughput
synthesis and high throughput screening - hts), the design
of new chemical libraries for bioassays has become a great
challenge for the medicinal chemists, leading to paradigm
changes, especially in the level of research conducted in the
industrial laboratories.
it is worth highlighting that, despite the substantial investment from the pharmaceutical industry sector in these
new technologies, the discovery of new chemical entities
(nces) that effectively represent an opportunity to reach the
market as authentic therapeutic innovations has not fulfilled
the expectations of the sector [8]. in fact, in 2005, among the
14 new medicines that came into the market, approved by the
american regulating agency (fda - food and drugs administration), with the exception of products with diagnosis
purposes, only ca. 50% of them had the status of authentic
nces [9].
in this context, the pharmaceutical industrial sector involved in the research of new drugs and medicines redirected
the structural design of collections of synthetic derivatives to
be bioassayed by hts, aiming at increasing the probability
of obtaining new hits candidate to drug prototypes, which
presented not only the appropriate pharmacophoric requisites, but also adequate solubility properties. the development of strategies with this purpose has been widely described in the literature and has led to the production of high
impact works. among others, we could mention the work of
lipinski and collaborators [10], who described the “rule of
the five”, based on the physicochemical properties of drugs
and lead-compounds described in the literature. the authors
postulated that an effectively promising lead-compound,
must have a maximum of 5 donor points and 10 hydrogen
© 2007 bentham science publishers ltd.

privileged structures in drug discovery

mini-reviews in medicinal chemistry, 2007, vol. 7, no. 11 1109

fig. (1). absolute number of annual citations of the term “privileged structures” in some bibliographic databases. the search was achieved
by using the term indicated above, year by year, and starting from 1988 to 2006. the databases signed with an asterisk (*) have the search
option in “full text”, activated in function of its availability.

bond acceptors (h-bond), molecular weight inferior to 500
atomic mass unities and calculated log p (clogp) inferior to
5. these rules have created empiric criteria for the structural
identification of new drug candidate compounds and have
also shown wide applicability in the construction of chemical
libraries [10].
the employment of the privileged structures concept in
the planning of new chemical libraries [11-12] has been associated with the use of computational methods and pharmacophoric models [13-14] or with the fragmentation of bioactive molecules, prototypes or drugs, and has allowed the
identification of relevant structural patterns that represent
authentic biophores, providing useful frameworks to the building of new compound databases [15-20].
schnur, hermsmeier and tebben [21], inventors of the
classpharmer program, useful for identification of frequent
(“privileged”) substructures in collections of bioactive
molecules, recently questioned the efficacy of the election of
privileged structures in the rational design of new compounds with selective properties against distinct biomolecular targets. these authors affirmed that just the frequency of
occurrence of certain structural subunits should not be the
table 1.

unique criteria to ensure its condition as privileged structures. in this context, they explored the question of the selectivity, identified in molecular fragments generated by their
program, in relation to distinct target-bioreceptor families:
g-protein-coupled receptors (gpcrs), nuclear hormone receptors (nhr), serine-proteases, kinase proteins and ionic
channels, recovering the original definition of evans [5] and
patchett [6]. furthermore, they noticed that there are high
percentages of occurrence of structures called privileged for
ionic channel ligands, among the serine-protease inhibitors
(92%) (table 1), as well as the fact that the privileged structures present in the latter occurred also in high percentage
(91%) in kinase inhibitors (table 1). on the other hand, the
authors observed that the inverse did not occur, i.e. only 11%
of the privileged structures identified as structural subunits
present in serine-protease inhibitors integrated the structures
of ionic channel ligands, and 20% of the privileged structures for kinase protein inhibitors were present in serineprotease inhibitors (table 1) [21].
besides, the same authors verified that the gpcr ligands
have wide diversity of privileged structures in relation to
other bioreceptor families, showing that these ligands are
more promiscuous and therefore present reduced selectivity

percentage of privileged structures present in gpcr, ionic channel, nhr, kinase-protein and serine-protease ligands*

ligands
sub-structures
gpcrs

a

ionic channels

nhrb

kinase-proteins

serine-proteases

gpcrs

-

26

10

11

17

ionic channels

47

-

15

19

92

nhr

40

30

-

17

15

kinase-proteins

48

34

16

-

20

11

7

91

-

serine-proteases

25
a

b

*adapted from reference [21]; g-protein coupled receptors; nuclear hormonal receptors.

mini-reviews in medicinal chemistry, 2007, vol. 7, no. 11

1110

n

h
n

o

o
ch3

duarte et al.

oh

o

h
n

cn
ho

o

o

o

a
o

a

o
a
a

h3c
ch3

cn
(3)
 xxxg1437xxx  inhibitor
[ref. 20]

h3co
(1)
bk1 antagonist
[ref. 18]

(2)
pkc inhibitor
[ref. 19]

o

(4)
 xxxg1893xxx  inhibitor
[ref. 21]

ho

o

cl
o

n
oh

n

n

co2h
b

b
 xxxd3487xxx  (6)
atii antagonist
[ref. 23]

losartan (5)
atii antagonist
[ref. 22]

n

n
n

n
n

nh

n

nh

fig. (2). privileged structures of biphenyl class (a) of compounds. it’s possible to notice the great variability of pharmacological targets to
derivatives presenting biphenyl subunit (a). this profile becomes restricted to  xxxg99xxx  receptor antagonists (at-ii) with the introduction of the 2’-tetrazolobiphenyl subunit (b).

[21]. taking as example the biphenyl substructure (a, fig.
(2)), classified as privileged structure for gpcrs [22,23],
schnur, hermsmeier and tebben [21] noticed that this
framework is present in 5658 compounds of distinct chemical classes that act in 311 different pharmacological targets,
e.g. bradykinin b1 (bk1) receptor antagonists (1) [24], protein kinase c (pkc) inhibitors (2) [25], type-3 metalloprotease inhibitors ( xxxg1437xxx ) (3) [26], protein  xxxg1893xxx  ( xxxg1893xxx ) inhibitors (4) [27] (fig. (2)). the privileged subunit 2’-tetrazolobiphenyl (b, fig. (2)) was identified in 1046 compounds strictly related to the blockage of
 xxxg99xxx  receptors, as illustrated by losartan (5) [28]
and  xxxd3487xxx  (6) [29] (fig. (2)). these data suggest that the
biphenyl privileged structure (a, fig. (2)) has its molecular
recognition modulated by the introduction of the tetrazole
subunit [21], isosteric to the carboxylate group, conducting
to the 2’-tetrazolobiphenyl pattern (b, fig. (2)), just like
evans [5] and patchett [6] preached in their original definitions of privileged structures.
identification of the privileged structures
benzodiazepines
the innovating works of evans and colleagues [5,30-32]
on the development of new non-peptidic cholecystokinin
(cck) receptor antagonists useful for the treatment of gastrointestinal disorders, such as pancreatitis and gastroe-

sophageal reflux, aimed at obtaining new analogs of the
natural product asperlicin (7) [33], cck-1 receptor antagonist with ic50 of 1.4 m, from the structural modification of
anxiolytic benzodiazepine drugs, e.g. diazepam (8) [5,3032]. these works culminated in the development of the
devazepide (l-364,718 or mk-329) (9), first nonpeptidic
benzodiazepine antagonist, highly selective for cck-1 receptors, with ic50 of 0.8 nm, used as a pharmacological
marker of this important therapeutic target. the structural
planning of (9) involved the molecular simplification of the
natural prototype (7), identifying the benzodiazepine ( xxxd1459xxx )
and tryptophan (trp) subunits as pharmacophoric points essential to the molecular recognition of (9) by the cck-1 receptors [5,30-32] (fig. (3)).
the benzodiazepines constitute a wide class of neuroactive compounds, acting as ionic channel and g proteincoupled receptor (gpcr) ligands. as important examples of
anxiolytic pharmaceuticals of this class, we can cite diazepam (8) and lorazepam (10), ligands of central gabaergic
receptors [34] (fig. (3) and (4)). in addition to the extensive
number of papers describing the activity of benzodiazepine
derivatives in the cck-1 receptors [5,30-32,35-45], there are
some cases in the literature in which the role of these compounds as ligands of other gpcrs is mentioned, such as opioid agonists, e.g.  xxxd3375xxx  (11) [46], useful in the treatment of the visceral pain, the platelet activation factor (paf)
antagonists of with antithrombotic activity, as the polycyclic

privileged structures in drug discovery

mini-reviews in medicinal chemistry, 2007, vol. 7, no. 11 1111

o

h3c
n
n

c

h
nh

simplification
oh h h
n

nh

n
h

n
ch3

o

 xxxd1459xxx 

o o

n

h

n

o

c

h3c
asperlicin (7)
ic50 cck-1 = 1.4 m
[ref. 27]

trp

h3c
c

cl

 xxxd1459xxx 

o

n

n

trp
devazepide (9)
ic50 cck-1 = 0.8 nm
ic50  xxxd1459xxx  = >100 m
[ref. 24-26]

diazepam (8)
ic50 cck-1 = >100 m
ic50  xxxd1459xxx  = 7 nm
[ref. 24-26]

fig. (3). structural design of devazepide (9).

derivative (12) with ic50 of 7 nm [47], the neurokinine
(nk)-1 receptor antagonists involved in the control of algesic and inflammatory events, e.g. (13) with pki of 8.0 [48]
and gpiibiiia receptor antagonists with antithrombotic profile, e.g. (14) with ic50 of 11 nm [49] (fig. (4)). among the
ones with enzyme inhibitor properties, it were described hiv
inverse transcriptase inhibitors such as nevirapine (15) with
ic50 of 84 nm [50], and ras-farnesyltransferase inhibitors,
useful for cancer treatment, exemplified by the derivative
bms-214662 (16) with ic50 of 1.4 nm [51] (fig. (4)). these
data characterize the benzodiazepine subunit (c, fig. (3) and
(4) as authentic privileged structure, able of being molecularly recognized by distinct sites of different bioreceptors.
dihydropyridines
another example of privileged structure is the dihydropyridine scaffold (d, fig. (5)) usually present in calcium
channel antagonist drugs, prescribed for the treatment of
hypertension, as illustrated by the amlodipine (17) [52] and
nifedipine (18) [53]. appropriate structural modifications of
the substituents of this privileged structure (d, fig. (5)) provided paf receptor antagonists, such as (19) [54];  xxxg84xxx  antagonists, useful as anti-inflammatories, exemplified by the derivative mrs 1097 (20) [55]; p2  xxxg1643xxx   xxxg1644xxx   xxxg1646xxx  modulators with anti-thrombotic activity, such
as mrs 2154 (21) [56] and 1a-adrenergic antagonists, prescribed for the treatment of benign prostatic hyperplasia,
illustrated by the derivative snap-6383 (22) [57], among
others (fig. (5)).
spiropiperidines
another important class of privileged structures is constituted of spiropiperidines (e, fig. (6)), which were initially
described as  xxxg1642xxx  antagonists, useful in the pre-

vention of preterm labor [58], and -opioid ligands [59], as
antipsychotic drug candidates. the derivative l-366,509 (23)
[58] (fig. (6)) was able to antagonize selectively the oxytocin hormone with ic50 of 0.78 m, in comparison with its
action on vasopressin receptors (ic50 v1 = 84 m; ic50 v2 =
83 m) [58]. the selectivity of (23) reveals the therapeutic
safety of this lead-compound, when referring to cardiovascular side effects [58]. on the other hand, the prototype l687.384 (24) (fig. (6)) represents an example of efficient opioid ligand, with pic50 of 8.42 [59].
patchett and collaborators [60] described the discovery of
the prototype mk-0667 (25) (fig. (6)) as a growth hormone
(gh) secretagogue, able of increasing the gh liberation into
pituitary cell cultures with ec50 of 1.3 nm. this compound
has also shown to be active in vivo, in dogs, when administered by oral route, despite possessing a peptidic subunit in
its structure [60]. additionally, mk-0667 did not alter the
levels of other metabolism regulatory hormones, such as
aldosterone, luteinizing hormone (lh), thyroxine and prolactin [60]. in fact, it was after the works of patchett and colleagues that the spiropiperidines (e, fig. (6)) were classified
as privileged structures. these structural subunits are present
in several other gpcr ligands, e.g. oxytocin and -opioid
receptors, as well as ionic channels and diverse enzymes
[6,61].
several other bioactive spiropiperidine derivatives are
related in literature, as exemplified by the derivative (26)
(fig. (6)), which present serotoninergic  xxxg1108xxx  antagonist (ki = 8.3 nm) and serotonin transporter (sert)
inhibitor (ki = 10 nm) properties, useful for the treatment of
anxiety and depression [62]. the derivative rs-504393 (27)
[63] represents an example of spiropiperidine antagonist of
chemokine 2b ( xxxg370xxx ) receptors, an antiinflammatory drug

1112

mini-reviews in medicinal chemistry, 2007, vol. 7, no. 11

c

h3c

o

h
n

duarte et al.

n

c

h3c

n

f

cl

n
s

(12)
paf agonist
ic50 = 7 nm
[ref. 41]

 xxxd3375xxx  (11)
-opioid agonist
[ref. 40]

lorazepam (10)
 xxxd1459xxx /gaba
[ref. 28]

h3c

o

h
n

c

o

cf3

ch3

n

n

n
o

o

c

oh

(14)
gpiibiiia antagonist
ic50 = 11 nm
[ref. 43]

h2n

cf3

(13)
nk1 antagonist
pki = 8.0
[ref. 42]

nh

hn
h
n

cl

n

c

ch3

n

c s

n

hn

n

n

cl

n

o

oh

o

n

o

o
n

c

n

n
n

bms-214662 (16)
ras-farnesyl
transferase inhibitor
ic50 = 1.4 nm
[ref. 45]

n

nc

nevirapine (15)
rt inhibitor
ic50 = 84 nm
[ref. 44]

o

s
s

o

fig. (4). privileged structures of the benzodiazepine (c) class.

cl

d
meo2c

co2et
o

h3c

no2

d

n
h

meo2c
nh2

ch3

co2me

h3c

n
h

ch3

eto2c

ch3
n

o

h3c

n
h

ch3
(19)
paf antagonist
[ref. 48]

nifedipine (18)
ca2+ blocker
[ref. 47]

amlodipine (17)
ca2+ blocker
[ref. 46]

o

d

f
f
o
d

o

d

eto2c

co2et

eto2c

o-nh4+

p

o-nh4+
h3c

n
h

mrs1097 (20)
a3 antagonist
[ref. 49]

h3c

n
h

n
n

fig. (5). privileged structures of the dihydropyridine (d) class.

co2me

n
h

ch3

mrs2154 (21)
p2 modulator
[ref. 50]

d

o
snap-6383 (22)
1a-adrenergic
antagonist
[ref. 51]

ome
n
h

privileged structures in drug discovery

mini-reviews in medicinal chemistry, 2007, vol. 7, no. 11 1113

o

o

s

ch3

n

n
o

n

n

e

e

e
oh

s

o

o

oh
o

l-366,509 (23)
oxytocin antagonist
ic50 = 0.78 m
[ref. 52]

o

o
l-387,384 (24)
-opioid ligand
pic50 = 8.42
[ref. 53]

mk-0667 (25)
gh secretagogue
ec50 = 1.3 nm
[ref. 54]

h2n

o

h
n

o

nh

o

o
s

ch3

n

o

n
e

n
e

n

n

e
o
o
ch3

oh
(26)
5-ht1a antagonist / sert
ki = 8.3 nm / 10 nm
[ref. 56]

rs-504393 (27)
 xxxg370xxx  antagonist
ic50 = 89 nm
[ref. 57]

hn
h
n
o

cl

(28)
mc4r antagonist
ic50 = 0.1 m
[ref. 58]

fig. (6). privileged structures of the spiropiperidine (e) class.

candidate, with ic50 of 89 nm (fig. (6)), and high selectivity
in comparison with other gpcrs, such as ccr1 (ic50 >
100000 nm), 1d (ic50 = 460 nm) and 5-ht1a (ic50 = 1070
nm) receptors. among the melanocortin-4 receptor (mc4r)
antagonists, it can be highlighted the spiropiperidine derivative (28) [64] (fig. (6)), which presented an ic50 of 0.1 m
and potential therapeutic application in metabolic disorders.
aminopyridazines
aminopyridazines represent an important class of bioactive compounds, which was elected as privileged structures
due to the presence of strategic points in the core framework,
whose the adequate manipulation was able to introduce a
structural diversity that allowed the building of oriented
chemical libraries [65]. the works of wermuth and colleagues explored this privileged structure, using the strategy
of selective optimization of side activities (sosa) [66-69].
this new approach consists in the structural modification of
old drugs with effective pharmacological activity against
new molecular targets, aiming at the optimization of these
interactions, with the advantage of knowing anticipatedly the
pharmacokinetic and toxicological behavior of the new drug
candidate [66-69].

in this context, wermuth and collaborators studied the
optimization of the side effects of the antidepressant drug
 xxxd2647xxx  (29) [66], which presented reduced affinity for  xxxg447xxx 
muscarinic receptors (ki = 17 m) [70-71] and for the  xxxg38xxx  enzyme ( xxxg38xxx ) (ic50 ~ 600 m) [72-73].
the  xxxg447xxx  muscarinic ligand sr 46559a (32) (ki = 3 nm) [7071] was obtained through the transposition of the methyl
group from c-3 to c-4 (29  30) of the pyridazinone ring
(f, fig. (7)), as well as the isosteric change of the morpholine subunit of (30) for a tropane ring, originating compound (31), and the subsequent introduction of a hydroxyl
group in the ortho position of the phenyl ring of (31), producing the desired derivative (32) (fig. (7)). the same molecular modification strategy was applied for obtaining the
derivative (36), a reversible  xxxg38xxx  inhibitor (ic50 = 0.01 m)
[72-73], by changing the lipophilic character of the ionizable
region of (29), resulting in the new piperidinic isoster (33).
subsequent modifications in the spacer size of (33) led to the
construction of the analogue (34) and, next, to (35), which by
conformational restriction led to (36) (fig. (7)).
diarylheterocycles
among the second generation of non-steroidal antiinflammatory agents, the diarylheterocyclic pattern (g, fig.

1114

mini-reviews in medicinal chemistry, 2007, vol. 7, no. 11

duarte et al.

ch3

o

n

f
nh
n

n

 xxxd2647xxx  (29)
antidepressive
ki  xxxg447xxx  = 17 m
ic50  xxxg38xxx  ~ 600 m
[ref. 60, 64-67]

n
f
nh
n

h3c

(33)
ic50  xxxg38xxx  = 13 m
[ref. 66-67]

f
nh
n

n

o

n

n

n
f

(30)
ki  xxxg447xxx  = 550 nm
[ref. 64-65]

nh
n

h3c

n

(34)
ic50  xxxg38xxx  = 1,9 m
[ref. 66-67]

n

f
nh
n

n

n

(31)
ki  xxxg447xxx  = 50 nm
[ref. 64-65]

f
nh
n

h3c

n

n

(35)
ic50  xxxg38xxx  = 0,12 m
[ref. 66-67]

n

f
nh
n
oh

f
nh

n
n

(32)
ki  xxxg447xxx  = 3 nm
[ref. 64-65]

n

(36)
ic50  xxxg38xxx  = 0,010 m
[ref. 66-67]

fig. (7). privileged structures of the aminopyridazine (f) class.

(8)) could be identified as privileged structure, being usually
present in cycloxigenase-2 (cox-2) inhibitors, e.g. celecoxib (37) [74] (ic50 = 0.04 m) and rofecoxib (38) [75]
(ic50 = 0.02 m); p38 mitogen activated kinase (p38
mapk) inhibitors, e.g.  xxxd3177xxx  (39) [76] (ic50 = 0.6 m)
and other prototypes with activity over multiple targets such
as cgs-2466 (40), which acts as adenosine  xxxg84xxx  antagonist, phosphodiesterase-4 (pde-4) and p38 mapk inhibitors [77] (fig. (8)). besides the antiinflammatory properties, these diarylheterocyclic derivatives can also act as inverse cannabinoid  xxxg479xxx  agonists, as illustrated by
rimonabant (41) [78] (ki = 5.6 nm);  xxxg874xxx  antagonists, e.g. (42) [77]; dopamine transport inhibitors, e.g.
(43) [77] (fig. (8)), characterizing its subunit as an authentic
privileged structure.

identification of the n-acylhydrazone
subunit (nah) as privileged structure
the works developed at lassbio with n-acylhydrazone
(nah) derivatives, recently compiled in fraga and barreiro’s revision [79], evidenced the privileged structure
character of this bioactive framework. the first series of bioactive nahs studied at lassbio was rationally planned
using medicinal chemistry tools concerning molecular
modification, such as molecular hybridization [80], bioisosterism [81], molecular simplification [82], homologation and
conformational restriction [83]. the employment of such
strategies allows the rational planning of important alterations of the lipophilic character, donor/acceptor h-bonding
sites, as well as in the distances and conformational orienta-

privileged structures in drug discovery

mini-reviews in medicinal chemistry, 2007, vol. 7, no. 11 1115

f3c

o
o

n
n
ch3
g

g
celecoxib (37)
cox-2 inhibitor
ic50 = 0.04 m
[ref. 68]

so2nh2
h3cos

rofecoxib (38)
cox-2 inhibitor
ic50 = 0.02 m
[ref. 69]

so2ch3

h2n
n

nh

cl

s

n
n

cl
g

g
 xxxd3177xxx  (39)
p38 mapk inhibitor
ic50 = 0.6 m
[ref. 70]

f

cgs-2466 (40)
a3 antagonist,
pde-4/p38 mapk inhibitor
[ref. 71]

n

cl
n
hn

o
ch3
s

nh
n

n

n
cl

cl

hn
n

n
cl

n-buo

g
cl

ch3

rimonabant (41)
cb1  xxxd1422xxx 
ki = 56 nm
[ref. 72]

g

g
o-nbu

(42)
glucagon antagonist
[ref. 71]

cl

(43)
da transport
blocker
[ref. 71]

fig. (8). privileged structures of the diarylheterocycle (g) class.

tions of the respective pharmacophoric groups, creating a
differentiation in the molecular recognition pattern of compounds of the same chemical class against different biomacromolecules, which result in distinct selectivity profiles [83].
from the molecular hybridization of two bioactive prototypes, i.e. bw-755c (44) [84] and cbs-1108 (45) [85], previously described as dual cyclooxygenase and  xxxg147xxx 
inhibitors, the first series of analgesic and antithrombotic 4nitropyrazole-5-hydrazone derivatives (46) was obtained
[86-87]. next, these compounds originated the pioneer pyrazolic nah series (47) (h, fig. (9)) through the classic bioisosterism among the nitro group, introduced in the series
(46) for synthetic conveniences [86], and carboxylate moiety, besides the transposition of the hydrazone group to the
carbon 4 of the n-phenylpyrazole system (fig. (9)), which
resulted in the obtainment of prototypes with important anal-

gesic [88] and platelet anti-aggregating properties [89]. these
results validated the structural planning of the new nah
series (47), demonstrating that the molecular modification
strategy adopted for the optimization of the initial series (46)
was appropriated.
the pharmacophoric character of the nah function was
investigated, through the suppression of the imine subunit of
(47) (fig. (9)), resulting in the respective amide derivatives
(47a), which showed to be inactive in the same bioassays
previously conducted. additionally, it is essential to highlight that nah pattern (h, fig. (10)) is characterized for
having different points of structural diversity, important in
the building of new families of bioactive drug-candidate prototypes. based on the bioisosterism strategies, other nah
series were synthesized and pharmacologically evaluated, in
order to allow the study of the relationships between the

1116

mini-reviews in medicinal chemistry, 2007, vol. 7, no. 11

duarte et al.

h2n
n
molecular
hybridization

n
n

s

n
s

n
h

cbs-1108 (45)

ch3

cf3

w

bw-755c (44)
ar
w

o
h3c

4

o

n+ o-

nh

ar

n

n
n

5

w
(47)

n

n
h

n

ar

n

bioisosterism

o
nh

(46)

(47a)

n
n

fig. (9). rational design of the n-acylhydrazone derivatives of series (44).

chemical structure and its respective analgesic, anti-inflammatory and antithrombotic activities [79].
initially, important bioisosteric relationships were identified among the analgesic nah derivatives lassbio-30
(47b) [88], lassbio-171 (48) [90], lassbio-208 (49) [91]
and lassbio-349 (50) [92], as well as among the platelet
anti-aggreganting compounds lassbio-35 (47c) [89] and
lassbio-602 (51) [93] (fig. (10)). these results suggested
that modifications in the heterocyclic pattern attached to the
acyl subunit did not modify drastically the pharmacological
profile of the new obtained compounds. however, the manipulation of the aryl subunit attached to the imine region
of nah framework, showed to be crucial to the observed
activity.
using the message-address concept introduced by lipkowski, tam and portoghese [94], it was observed that the
nah class have a differentiated pattern of pharmacological
activity (message) when the imine region (k, fig. (10)) was
modified and different binding patterns (address) were introduced when the nature of the acyl-bound subunit (j, fig.
(10)) was changed. in fact, modifying rationally these two
structural subunits we were able to obtain platelet antiaggreganting compounds, illustrated by lassbio-35 (47c)
[89] and lassbio-602 (51) [93]; peripheral analgesics, such
as lassbio-30 (47b) [88], lassbio-171 (48) [90], lassbio-208 (49) [91], lassbio-349 (50) [92] and lassbio891 (52) [95] (fig. (10)); central analgesics, such as lassbio-417 (53) [96], based on the structure of the antipsychotic
chlorpromazine (54), and the non-selective cannabinoid receptor ligand lassbio-881 (55) [97]; cruzipain inhibitors,

such as lassbio-334 (56) [98], originated from the structure of the derivative zli48a (57); cardiotonic agents, such
as lassbio-294 (58) [99] and vasoactive derivatives, such
as lassbio-785 (59) [100], based on the structure of the
 xxxg1695xxx  inhibitor, imazodan (60) (fig. (10)).
considering the synthetic accessibility of the nah derivatives, it was noticed that rational modification of their
sub-unities resulted in more selective compounds for certain
pharmacological targets. this particular structural profile
became possible to label the nah framework as a privileged
structure, respecting the original definition of evans [5] and
patchett [6], considering that it is able of contributing to the
molecular recognition for a wide number of biological targets, whose appropriate structural modification of their substituents.can result in selective compounds for a defined
pharmacological action.
conclusion
the concept of privileged structures, in its more strict
definition, represents important tool for the identification of
new structural subunits that contribute as pharmacophoric
points for different pharmacologic activities [5-6]. on the
previously mentioned works, the privileged structures represented by biphenyls, benzodiazepines, dihydropyridines, spiropiperidines, aminopyridazines, diaryl-heterocycles and nah
stood out. this new tool of understanding bioactive molecular diversity has been employed in the “colonization” of the
existing therapeutic space for each molecular framework
[100] and in association with other classical medicinal
chemistry concepts [101] has assisted the rational design of
new drug-candidate prototypes.

privileged structures in drug discovery

mini-reviews in medicinal chemistry, 2007, vol. 7, no. 11 1117

o

 xxxg1569xxx 

o

 xxxg1569xxx 

o

h3c
n

j

n
h

n

n

k

br
o
oh

n

n
h

hn

lassbio-171 (48)
analgesic
[ref. 90]

n
h

n

n

h

n

n

j

o

h3c

k

n

k

lassbio-35 (47c)
anti-platelet
[ref. 89]

 xxxg1569xxx 

n
h

n

h

o
h

n

lassbio-208 (49)
analgesic
[ref. 91]

j

o
o

n
h

n

k

n

lassbio-30 (47b)
analgesic
[ref. 88]

j

n
h

n

h

n

n
j

k

lassbio-602 (51)
anti-platelet
ic50 (aa) = 2.2 m
[ref. 93]

h

n
j

lassbio-349 (50)
analgesic
ed50 = 18.8 mol/kg
[ref. 92]

meo

k
h

n

cl

o
br

nh

o

o

s

n
n
h

j

n
h

j

k
h

lassbio-417 (53)
central analgesic
[ref. 96]

o

ho

n

o

n
n

s

j

h
n

oh

n
imazodan (60)
 xxxg1695xxx  inhibitor

zli48a (57)
cruzipain inhibitor

j

o

oh

o

h

k

o
n

o

k

n
n
h

n

o

o
o

j

n
h

k

o

k

n

n

chlorpromazine (54)
antipsychotic

n

k

o
cl

nh

k

lassbio-785 (59)
vasoactive
[ref. 100]

ho
j

o

h

ch3

o

h

lassbio-334 (56)
cruzipain inhibitor
[ref. 98]

j

n

k

h

lassbio-294 (58)
cardiotonic
[ref. 99]

s

n

n
n

j

s

o

o
n
h

n
h

h

k
h3c

n

o
k

n

no2

n
h
j

h

no2
lassbio-881 (55)
central analgesic
[ref. 97]

lassbio-891 (52)
peripheral analgesic
[ref. 95]

fig. (10). privileged structures of the n-acylhydrazone (h) class.

acknowledgements

references

thanks are due to im-inofar (br, #420.015/05-1),
pronex-rio (br), cnpq (br), faperj (br), capes
(br) and fujb (br) for the financial support and fellowships.

[1]
[2]

wermuth, c. g.; ganellin, c. r.; lindberg, p.; mitscher, l. a.
pure appl. chem., 1998, 70, 1129.
monge, a.; chorghade, m.; erhardt, p. w.; ganellin, c. r.; koga,
n.; lindberg, p.; perun, t. j.; topliss, j. g.; trivedi, b. k.; wermuth, c. g. eur. j. med. chem., 2000, 35, 1121.

1118

mini-reviews in medicinal chemistry, 2007, vol. 7, no. 11

[3]

barreiro, e. j.; fraga, c. a. m. química medicinal: as bases
moleculares da ação dos fármacos, artmed: porto alegre, 2001;
pp. 15-51.
barreiro, e. j.; fraga, c. a. m. química medicinal: as bases
moleculares da ação dos fármacos, artmed: porto alegre, 2001;
pp. 163-210.
evans, b. e.; rittle, k. e.; bock, m. g.; dipardo, r. m.; freidinger, r. m.; whitter, w. l.; lundell, g. f.; veber, d. f.; anderson, p. s.; chang, r. s. l.; lotti, v. j.; cerino, d. j.; chen, t. b.;
kling, p. j.; kunkel, k. a.; springer, j. p.; hirshfieldt, j. j. med.
chem., 1988, 31, 2235.
patchett, a. a.; nargund, r. p. annu. rep. med. chem., 2000, 35,
289.
the searched bibliographic databases were: web of science®
(http://isiknowledge.com), american chemical society (acs; http://
pubs.acs.org), science direct® (http://www.sciencedirect.com) e scifinder scholar® (cas chemical abstracts service), accessed from the
brazilian site http://www.periodicos.capes.gov.br in march 05, 2007.
service, r. f. science, 2004, 303, 1796.
http://www.centerwatch.com/patient/drugs/drugls05.html, accessed
in march 20, 2006.
lipinski, c. a.; lombardo, f.; dominy, b. w.; feeney, p. j. adv.
drug deliv. rev., 1997, 23, 3.
thompson, l. a.; ellman, j. a. chem. rev., 1996, 96, 555.
ellman, j. a. acc. chem. res., 1996, 29, 132; lebl, m. j. comb.
chem., 1999, 1, 3.
labaudinière, r. f. drug discov. today, 1998, 3, 511.
mason, j. s.; morize, i.; menard, p. r.; cheney, d. l.; hulme, c.;
labaudinière, r. f. j. med. chem., 1999, 42, 3251.
bemis, g. w.; murcko, m. a. j. med. chem., 1999, 42, 5095.
bemis, g. w.; murcko, m. a. j. med. chem., 1996, 39, 2887.
lewell, x. q.; judd, d. b.; watson, s. p.; hann, m. m. j. chem.
inf. comp. sci., 1998, 38, 511.
sheridan, r. p.; miller, m. d. j. chem. inf. comp. sci., 1998, 38,
915.
ajay; bemis, g. w.; murcko, m. a. j. med. chem., 1999, 42,
4942.
schnur, d. m.; beno, b. r.; good, a.; tebben, a. j. chemoinformatics: concepts, methods and tools for drug discovery, methods in molecular biology, humana press: totowa, 2004; pp. 355378.
schnur, d. m.; hermsmeier, m. a.; tebben, a. j. j. med. chem.,
2006, 49, 2000.
bemis, g. w.; murcko, m. a. j. med. chem., 1996, 39, 2887.
mason, j. s.; morize, i.; menard, p. r.; cheney, d. l.; hulme, c.;
labaudinière, r. f. j. med. chem., 1999, 42, 3251.
kuduk, s. d.; ng, c.; feng, d.-m.; wai, j. m.-c.; chang, r. s. l.;
harrell, c. m.; murphy, k. l.; ransom, r. w.; reiss, d.; ivarsson,
m.; mason, g.; boyce, s.; tang, c.; prueksaritanont, t.; freindinger, r. m.; pettibone, p. j.; bock, m. g. j. med. chem., 2004, 47,
6439.
duan, d.; lewin, n. e.; sigano, d. m. blumberg, b. m.; marquez,
v. e. j. med. chem., 2004, 47, 3248.
erlanson, d.a.; mcdowell, r. s.; o’brien, t. j. med. chem., 2004,
47, 3463.
malamas, m. s.; sredy, j.; moxham, c. katz, a.; xu, w. x.;
mcdevitt, r.; adebayo, f. o.; sawicki, d. r.; seestaller, l.; sullivan, d.; taylor, j. r. j. med. chem., 2000, 43, 1293.
kauffman, r. f.; bean, j. s.; zimmerman, k. m.; brown, r. f.;
steinberg, m. i. life sci., 1991, 49, pl223.
buhlmayer, p.; furet, p.; criscione, l.; degasparo, m.; whitebread, s.; schmidlin, t.; lattmann, r.; wood, j. bioorg. med.
chem. lett., 1994, 4, 29.
bock, m. g.; dipardo, r. m.; rittle, k. e. evans, b. e.; freidinger,
r. m.; veber, d. f.; chang, r. s. l.; chen, t. b.; keegan, m. e.;
lotti, v. j. j. med. chem., 1986, 29, 1941.
evans, b. e.; bock, m. g.; rittle, k. e.; dipardo, r. m.; whitter,
w. l.; veber, d. f.; anderson, p. s.; freidinger, r. m. proc. natl.
acad. sci. usa, 1986, 83, 4918.
bock, m. g.; dipardo, r. m.; evans, b. e.; rittle, k. e.; veber, d.
f.; freidinger, r. m.; chang, r. s. l.; lotti, v. j. j. med. chem.,
1988, 31, 176.
chang, r. s. l.; lotti, v. j.; monaghan, r. l.; birnbaum, j.; stapley, e. o.; goetz, m. a.; albersschonberg, g.; patchett, a. a.; liesch, j. m.; hensens, o. d.; springer, j. p. science, 1985, 230, 177.

[4]
[5]

[6]
[7]

[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
[17]
[18]
[19]
[20]

[21]
[22]
[23]
[24]

[25]
[26]
[27]
[28]
[29]

[30]
[31]

[32]
[33]

duarte et al.
[34]
[35]
[36]

[37]
[38]

[39]
[40]

[41]

[42]

[43]
[44]
[45]
[46]
[47]
[48]

[49]

[50]

[51]

[52]
[53]

[54]
[55]
[56]
[57]

sternbach, l. e. j. med. chem., 1979, 22, 1.
bock, m. g.; dipardo, r. m.; evans, b. e.; rittle, k. e.; whitter,
w. l.; veber, d. f.; freidinger, r. m.; chang, r. s. l.; chen, t.
b.; lotti, v. j. j. med. chem., 1990, 33, 450.
bock, m. g.; dipardo, r. m.; evans, b. e. rittle, k. e.; whitter,
w. l.; garsky, v. m.; gilbert, k. f.; leighton, j. l.; carson, k. l.;
mellin, e. c.; veber, d. f.; chang, r. s. l.; lotti, v. j.; freedman,
s. b.; smith, a. j.; patel, s.; anderson, p. s.; freidinger, r. m. j.
med. chem., 1993, 36, 4276.
lowe, iii, j. a.; hageman, d. l.; drozda, s. e.; mclean, s.; brice,
d,. k.; crawford, r. t.; zorn, s.; morrone, j.; bordner, j. j. med.
chem., 1994, 37, 3789.
van niel, m. b.; freedman, s. b.; matassa, v. g.; patel, s.;
pengilley, r. r.; smith, a. j. bioorg. med. chem. lett., 1995, 5,
1421.
curotto, g.; donati, d.; pentassuglia, g.; ursini, a. bioorg. med.
chem. lett., 1995, 5, 3011.
henke, b. r.; willson, t. m.; sugg, e. e.; croom, d. k.;
dougherty-jr., r. w.; queen, k. l.; birkemo, l. s.; ervin, g. n.;
grizzle, m. k.; johnson, m. f.; james, m. k. j. med. chem., 1996,
39, 2655.
hirst, g. c.; aquino, c.; birkemo, l.; croom, d. k.; dezube, m.;
dougherty-jr., r. w.; ervin, g. n.; grizzle, m. k.; henke, b.;
james, m. k.; momtahen, t.; queen, k. l.; sherrill, r. g.; szewczyk, j.; willson, t. m.; sugg, e. e. j. med. chem., 1996, 39,
5236.
henke, b. r.; aquino, c. j.; birkemo, l. s.; croom, d. k.;
dougherty-jr., r. w.; ervin, g. n.; grizzle, m. k.; hirst, g. c.;
james, m. k.; johnson, m. f.; queen, k. l.; sherrill, r. g.; sugg,
e. e.; suh, e. m.; szewczyk, j.; unwalla, r. j.; yingling, j.; willson, t. m. j. med. chem., 1997, 40, 2706.
sinha, j.; kurup, a.; paleti, a.; gupta, s. p. bioorg. med. chem.,
1999, 7, 1127.
agrawal, v. k.; sharma, r.; khadikar, p. v. bioorg. med. chem.,
2002, 10, 3571.
giragossian, c.; sugg, e. e.; szewczyk, j. r.; mierke, d. f. j.
med. chem., 2003, 46, 3476.
römer, d.; büscher, h. h.; hill, r. c. maurer, r.; petcher, t. j.;
zeugner, h.; benson, w.; finner, e.; milkowski, w.; thies, p. w.
nature, 1982, 298, 759.
walser, a.; flynn, t.; mason, c.; crowley, h.; maresca, c.;
yaremko, b.; o’donnel, m. j. med. chem., 1991, 34, 1209.
armour, d. r.; aston, n. m.; morriss, k. m. l.; congreve, m. s.;
hawcock, a. b.; marquess, d.; mordaunt, j. e.; richards, s. a.;
ward, p. bioorg. med. chem. lett., 1997, 7, 2037.
mcdowell, r. s.; blackburn, b. k.; gadek, t. r.; mcgee, l. r.;
rawson, t.; reynolds, m. e.; robarge, k. d.; somers, t. c.;
thorsett, e. d.; tischler, m.; webb, ii, r. r.; venuti, m. c. j. am.
chem. soc., 1994, 116, 5077.
hargrave, k. d.; proudfoot, j. r.; grozinger, k. g.; cullen, e.;
kapadia, s. r.; patel, u. r.; fuchs, v. u.; mauldin, s. c.; vitous,
j.; behnke, m. l.; klunder, j. m.; pal, k.; skiles, j. w.; mcneil,
d. w.; rose, j. m.; chow, g. c.; skoog, m. t.; wu, j. c.;
schmidt, g.; engel, w. w.; eberlein, w. g.; saboe, t. d.; campbell, s. j.; rosenthal, a. s.; adams, j. j. med. chem., 1991, 34,
2231.
hunt, j. t.; ding, c. z.; batorsky, r. bednarz, m.; bhide, r.; cho,
y.; chong, s.; chao, s.; gullo-brown, j.; guo, p.; kim, s. h.; lee,
f. y. f.; leftheris, k.; miller, a.; mitt, t.; patel, m.; penhallow, b.
a.; ricca, c.; rose, w. c.; schmidt, r.; slusarchyk, w. a.; vite,
g.; manne, v. j. med. chem., 2000, 43, 3587.
arrowsmith, j. e.; campbell, s. f.; cross, p. e.; stubbs, j. k.;
burges, r. a.; gardiner, d. g.; blackburn, k. j. j. med. chem.,
1986, 29, 1696.
vater, w.; schlossm, k.; stoepel, k.; saller, h.; meng, k.; oberdorf, a.; puls, w.; schlossmann, k.; stoepel, k. arzneim.-forsch.,
1972, 22, 1.
sunkel, c. e.; de casa-juana, m. f.; santos, l.; gomes, m. m.;
villaroya, m.; gonzalez-morales, m. a.; priego, j. g.; ortega, m.
p. j. med. chem., 1990, 33, 3205.
van rhee, a. m.; jiang, j.-i.; melman, n.; olah, m. e.; stiles, g.
l.; jacobson, k. a. j. med. chem., 1996, 39, 2980.
jacobson, k. a.; kim, y.-c.; king b. f. j. auton. nerv. syst.,
2000, 81, 152.
lagu, b. drugs future, 2001, 26, 757.

privileged structures in drug discovery
[58]

[59]
[60]

[61]
[62]

[63]

[64]
[65]
[66]
[67]
[68]
[69]
[70]
[71]

[72]
[73]
[74]

[75]

[76]

mini-reviews in medicinal chemistry, 2007, vol. 7, no. 11 1119

evans, b. e.; leighton, j. l.; rittle, k. e.; gilbert, k. f.; lundell,
g. f.; gould, n. p.; hobbs, d. w.; dipardo, r. m.; veber, d. f.;
pettibone, d. j.; clineschmitt, b. v.; anderson, p. s.; freidinger,
r. m. j. med. chem., 1992, 35, 3919.
chambers, m. s.; baker, r.; billington, d. c.; knight. a. k.; middlemiss, d. m.; wong, e. h. f. j. med. chem., 1992, 35, 2033.
patchett, a. a.; nargund, r. p.; tata, j. r.; chen, m. h.; barakat,
k. j.; johnston, d. b. r.; cheng, k.; chan, w. w. s.; butler, b.;
hickey, g.; jacks, t.; schleim, k.; pong, s. s.; chaung, l. y. p.;
chen, h. y.; frazier, e.; leung, k. h.; chiu, s. h. l.; smith, r. g.
proc. natl. acad. sci. usa, 1995, 92, 7001.
nargund, r. p.; patchett, a. a.; bach, m. g.; murphy, m. g.;
smith, r. g. j. med. chem., 1998, 41, 3103.
van niel, m. b.; beer, m.; castro, j.; cheng, s. k. f.; evans, d.
c.; heald, a.; hitzel, l.; hunt, p.; mortishire-smith, r.;
o’connor, d.; watt, a. p.; macleod, a. m. bioorg. med. chem.
lett., 1999, 9, 3243.
mirzadegan, t.; dihel, f.; ebi, b.; bhakta, s.; polsky, i.; mccarley, d.; mulkins, m.; weatherhead, g. s.; lapierre, j. r.; dankwardt, j.; morgans, d.; wilhelm, r.; jarnagin, k. j. biol. chem.,
2000, 275, 25562.
bondensgaard, k.; ankersen, m.; thögersen, h.; hansen, b. s.;
wulff, b. s.; bywater, r. p. j. med. chem., 2004, 47, 888.
bourguignon, j. j.; oumouch, s.; schmitt, m. curr. org. chem.,
2006, 10, 277.
wermuth, c. g. j. med. chem., 2004, 47, 1303.
wermuth, c. g. j. heterocycl. chem., 1998, 35, 1091.
wermuth, c. g.; clarence-smith, k. pharm. news, 2000, 7, 53.
wermuth, c. g. med. chem. res., 2001, 10, 431.
wermuth, c. g.; bourguignon, j. j.; hoffmann, r.; boigegrain, r.;
brodin, r.; kan, j. p.; soubrie, p. bioorg. med. chem. lett., 1992,
2, 833.
kan, j.-p.; steinberg, r.; oury-donat, f.; michaud, j.-c.; thurneyssen, o.; terranova, j.-p.; gueudet, c.; souilhac, j.; brodin, r.;
boigegrain, r.; wermuth, c. g.; worms, p.; soubrie, p.; le fur,
g. psychopharmacology, 1993, 112, 219.
contreras, j.-m.; rival, y. m.; chayer, s.; bourguignon, j.-j.;
wermuth, c. g. j. med. chem., 1999, 42, 730.
contreras, j.-m.; parrot, i.; sippl, w.; rival, y. m.; wermuth, c.
g. j. med. chem., 2001, 44, 2707.
penning, t. d.; talley, j. j.; bertenshaw, s. r.; carter, j. s.;
collins, p. w.; docter, s.; graneto, m. j.; lee, l. f.; malecha, j.
w.; miyashiro, j. m.; rogers, r. s.; rogier, d. j.; yu, s. s.; anderson, g. d.; burton, e. g.; cogburn, j. n.; gregory, s. a.; koboldt, c. m.; perkins, w. e.; seibert, k.; veenhuizen, a. w.;
zhang, y. y.; isakson, p. c. j. med. chem., 1997, 40, 1347.
prasit, p.; wang, z.; brideau, c.; chan, c. c.; charleson, s.;
cromlish, w.; ethier, d.; evans, j. f.; ford-hutchinson, a. w.;
gauthier, j. y.; gordon, r.; guay, j.; gresser, m.; kargman, s.;
kennedy, b.; leblanc, y.; leger, s.; mancini, j.; o'neill, g. p.;
ouellet, m.; percival, m. d.; perrier, h.; riendeau, d.; rodger, i.;
tagari, p.; therien, m.; vickers, p.; wong, e.; xu, l. j.; young, r.
n.; zamboni, r.; boyce, s.; rupniak, n.; forrest, n.; visco, d.;
patrick, d. bioorg. med. chem. lett., 1999, 9, 1773.
cuenda, a.; rouse, j.; doza; y. n.; meier, r.; cohen, p.; gallagher, t. f.; young, p. r.; lee, j. c. febs lett., 1995, 364, 229.

received: 07 may, 2007

revised: 30 may, 2007

accepted: 31 may, 2007

[77]
[78]
[79]
[80]
[81]
[82]
[83]
[84]
[85]
[86]
[87]
[88]
[89]
[90]
[91]
[92]
[93]

[94]
[95]

[96]
[97]

[98]
[99]
[100]
[101]

müller, g. drug discov. today, 2003, 8, 681.
barth, f. annu. rep. med. chem., 2005, 40, 103.
fraga, c. a. m.; barreiro, e. j. curr. med. chem., 2006, 13, 167.
viegas-jr, c.; danuello, a.; bolzani, v. s.; barreiro, e. j.; fraga,
c. a. m. curr. med. chem., 2007, 14, 1829.
lima, l. m.; barreiro, e. j. curr. med. chem., 2005, 12, 23.
barreiro, e. j. quim. nova, 2002, 22, 1172.
wermuth, c. g. the practice of medicinal chemistry, academic
press: nova iorque, 1996.
ghiglieri-bertez, c.; coquelet, c.; alazet, a.; bonne, c. eur. j.
med. chem., 1987, 22, 147.
sincholle, d.; bertez, c.; legrand, a.; conduzorgues, j. p.; bonne,
c. arzneim.-forsch., 1985, 35-2, 1260.
freitas, a. c. c. phd thesis, federal university of rio de janeiro,
rio de janeiro, 1992.
silveira, i. a. f. b.; paulo, l. g.; miranda, a. l. p.; barreiro, e. j.;
freitas, a. c. c. j. pharm. pharmacol., 1993, 45, 646.
matheus, m. e.; oliveira, l. f.; freitas, a. c. c.; carvalho, a. m.
a. s. p.; barreiro, e. j. braz. j. med. biol. res., 1991, 24, 1219.
miranda, a. l. p.; soler, o.; freitas, a. c. c.; barreiro, e. j. j.
physiol. pharmacol., 1994, 72, 210.
leite, l. f. c. c.; neves, m. r.; da-silva, j. b. p.; miranda, a. l.
p.; fraga, c. a. m.; barreiro, e. j. farmaco, 1999, 54, 747.
ribeiro, i. g.; silva, k. c. m.; parrini, s. c.; miranda, a. l. p.;
fraga, c. a. m.; barreiro, e. j. eur. j. med. chem., 1998, 33, 225.
figueiredo, j. m.; camara, c. d.; amarante, e. g.; miranda, a. l.
p.; santos, f. m.; rodrigues, c. r.; fraga, c. a. m.; barreiro, e. j.
bioorg. med. chem., 2000, 8, 2243.
cunha, a. c.; figueiredo, j. m.; tributino, j. l. m.; miranda, a. l.
p.; castro, h. c.; zingali, r. b.; fraga, c. a. m.; de souza, m. c.
b. v.; ferreira, v. f.; barreiro, e. j. bioorg. med. chem., 2003, 11,
2051.
lipkowski, a. w.; tam, s. w.; portoghese, p. s. j. med. chem.,
1986, 29, 1222.
bezerra-netto, h. j. c.; lacerda, d. i.; miranda, a. l. p.; alves, h.
m.; barreiro, e. j.; fraga, c. a. m. bioorg. med. chem., 2006, 14,
7924.
silva, g. a.; costa, l. m. m.; brito, f. c. f.; miranda, a. l. p.;
barreiro, e. j.; fraga, c. a. m. bioorg. med. chem., 2004, 12,
3149.
duarte, c. d.; tributino, j. l. m.; lacerda, d. i.; martins, m. v.;
alexandre-moreira, m. s.; dutra, f.; bechara, e. j. h.; de-paula,
f. s.; goulart, m. o. f.; ferreira, j.; calixto, j. b.; nunes, m. p.;
bertho, a. l.; miranda, a. l. p.; barreiro, e. j.; fraga, c. a. m.
bioorg. med. chem., 2007, 15, 2421.
ifa, d. r.; rodrigues, c. r.; alencastro, r. b.; fraga, c. a. m.;
barreiro, e. j. theochem-j. mol. struct., 2000, 505, 11.
gonzalez-serratos, h.; chang, r.; pereira, e. f. r.; castro, n. g.;
aracava, y.; melo, p. a.; lima, p. c.; fraga, c. a. m.; barreiro, e.
j.; albuquerque, e. x. j. pharmacol. exp. ther., 2001, 299, 558.
silva, a. g.; zapata-sudo, g.; kummerle, a. e.; fraga, c. a. m.;
barreiro, e. j.; sudo, r. t. bioorg. med. chem., 2005, 13, 3431.
kubinyi, h. in analogue-based drug-discovery; fischer, j.; ganellin, c. r., eds.; wiley-vhc verlag: weinheim, 2006; pp. 53-68.

